N-(4-methanesulfonyl-benzyl)-formamide | 98996-51-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-methanesulfonyl-benzyl)-formamide
• 英文别名: N-(4-Methansulfonyl-benzyl)-formamid；N-(4-Methylsulfon-benzyl)-formamid；N-[(4-methylsulfonylphenyl)methyl]formamide
• CAS: 98996-51-1
• 化学式: C₉H₁₁NO₃S
• 分子量: 213.257
• InChiKey: APADBYZAINSRCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-formamid 在 sodium sulfite 作用下， 生成 N-(4-methanesulfonyl-benzyl)-formamide
  参考文献：
  名称：

  Momose; Schoji, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1950, vol. 70, p. 616

  摘要：

  DOI：

文献信息

• [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
  申请人：VIAMET PHARMACEUTICALS INC

  公开号：WO2013090210A1

  公开（公告）日：2013-06-20

  The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

  这项即时发明描述了具有金属酶调节活性的化合物，以及治疗由这些金属酶介导的疾病、疾病或症状的方法。
• Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
  申请人：Miyazaki Susumu

  公开号：US20050054645A1

  公开（公告）日：2005-03-10

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及一种由下式[I]所表示的含氮融合环化合物，其中每个符号如规范中定义，或其药学上可接受的盐，以及含有该化合物的抗HIV剂。本发明的化合物具有HIV整合酶抑制活性，并可用作预防或治疗艾滋病的药剂，或作为抗HIV剂。此外，通过与其他抗HIV剂（如蛋白酶抑制剂、逆转录酶抑制剂等）的联合使用，可使其成为更有效的抗HIV剂。由于显示出整合酶特异性高抑制活性，该化合物可作为对人体安全的药物剂，仅引起较少的副作用。
• Azaindazole Compounds As CCR1 Receptor Antagonists
  申请人：COOK Brian Nicholas

  公开号：US20120035370A1

  公开（公告）日：2012-02-09

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.

  本发明涉及一种式（I）的化合物，用于治疗多种通过CCR1活性介导或维持的疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。本发明还涉及其中间体以及制备和使用该化合物的方法。
• NITROGENOUS CONDENSED-RING COMPOUND AND USE THEREOF AS HIV INTEGRASE INHIBITOR
  申请人：Japan Tobacco Inc.

  公开号：EP1544199A1

  公开（公告）日：2005-06-22

  The present invention relates to a nitrogen-containing fused ring compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing such compound. The compound of the present invention has an HIV integrase inhibitory activity, and is useful as an agent for the prophylaxis or treatment of AIDS, or as an anti-HIV agent. In addition, by the combined use with other anti-HIV agents such as a protease inhibitor, a reverse transcriptase inhibitor and the like, it can be a more effective anti-HIV agent. Becuae it shows integrase-specific high inhibitory activity, the compound can be a pharmaceutical agent safe on human body, which causes only a fewer side effects.

  本发明涉及由下式[I]表示的含氮融合环化合物 其中各符号如说明书中所定义，或其药学上可接受的盐，以及含有这种化合物的抗HIV制剂。本发明的化合物具有抑制 HIV 整合酶的活性，可用作预防或治疗艾滋病的药物，或用作抗 HIV 药物。此外，通过与蛋白酶抑制剂、逆转录酶抑制剂等其他抗艾滋病毒药物联合使用，它可以成为一种更有效的抗艾滋病毒药物。由于该化合物对整合酶具有特异性的高抑制活性，因此是一种对人体安全的药物，副作用较小。
• SULFONYLUREA DERIVATIVE CAPABLE OF SELECTIVELY INHIBITING MMP-13
  申请人：Shionogi&Co., Ltd.

  公开号：EP2128134A1

  公开（公告）日：2009-12-02

  A compound represented by the general formula (I): wherein R1 is wherein R26 and R28 are each independently lower alkyloxy and the like; n1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula: wherein R6 and R7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R2 is a hydrogen atom and the like; R3 is optionally substituted lower alkyl and the like; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.

  通式 (I) 所代表的化合物： 其中 R1 是 其中 R26 和 R28 各自独立地为低级烷氧基等；n1 为 0 至 3 的整数；Z 为任选取代的 C1-C5 烯烃，可被选自取代基 a 等的取代基打断；A 为由式（I）表示的基团： 其中 R6 和 R7 各自独立地为低级烷基等；m 和 n 各自独立地为 0、1 或 2；R2 为氢原子等；R3 为任选取代的低级烷基等；R4 为氢原子；或 R3 和 R4 可与相邻碳原子一起构成环；R5 为羟基等，或其光学活性异构体、药学上可接受的盐或溶液。